2025 ICD-10-CM Diagnosis Code C85.9

by

Non-Hodgkin lymphoma, unspecified

  • C85.9 should not be used for reimbursement purposes as there are multiple codes below it that contain a greater level of detail.
  • The 2025 edition of ICD-10-CM C85.9 became effective on October 1, 2024.
  • This is the American ICD-10-CM version of C85.9 – other international versions of ICD-10 C85.9 may differ.

Applicable To

  • Lymphoma NOS
  • Malignant lymphoma NOS
  • Non-Hodgkin lymphoma NOS

The following code(s) above C85.9 contain annotation back-references

 that may be applicable to C85.9:

  • C00-D49  Neoplasms
  • C81-C96  Malignant neoplasms of lymphoid, hematopoietic and related tissue
  • C85  Other specified and unspecified types of non-Hodgkin lymphoma

Clinical Information

  • A general term for various neoplastic diseases of the lymphoid tissue.
  • A group of cancers of the lymphoid system, including acute lymphoblastic leukemia, b-cell lymphoma, burkitt’s lymphoma, diffuse cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, lymphoblastic lymphoma, mantle cell lymphoma, mycosis fungoides, post-transplantation lymphoproliferative disorder, small non-cleaved cell lymphoma, and t-cell lymphoma.
  • A malignant (clonal) proliferation of b- lymphocytes or t- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites. This category includes non-hodgkin lymphomas and hodgkin lymphomas.
  • A malignant neoplasm composed of lymphocytes of b- or t/nk-cell phenotype.
  • Any of a group of malignant tumors of lymphoid tissue that differ from hodgkin disease, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant reed-sternberg cells, a characteristic of hodgkin’s disease.
  • Any of a large group of cancers of lymphocytes (white blood cells). Nhls can occur at any age and are often marked by lymph nodes that are larger than normal, fever, and weight loss. There are many different types of nhl. These types can be divided into aggressive (fast-growing) and indolent (slow-growing) types, and they can be formed from either b-cells or t-cells. B-cell nhls include burkitt lymphoma, chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), diffuse large b-cell lymphoma, follicular lymphoma, immunoblastic large cell lymphoma, precursor b-lymphoblastic lymphoma, and mantle cell lymphoma. T-cell nhls include mycosis fungoides, anaplastic large cell lymphoma, and precursor t-lymphoblastic lymphoma. Lymphomas that occur after bone marrow or stem cell transplantation are usually b-cell nhls. Prognosis and treatment depend on the stage and type of disease.
  • Cancer that begins in cells of the immune system. There are two basic categories of lymphomas. One kind is hodgkin lymphoma, which is marked by the presence of a type of cell called the reed-sternberg cell. The other category is non-hodgkin lymphomas, which includes a large, diverse group of cancers of immune system cells. Non-hodgkin lymphomas can be further divided into cancers that have an indolent (slow-growing) course and those that have an aggressive (fast-growing) course. These subtypes behave and respond to treatment differently. Both hodgkin and non-hodgkin lymphomas can occur in children and adults, and prognosis and treatment depend on the stage and the type of cancer.
  • Characterized by malignant lymphomas; clinically similar to hodgkin’s disease, except that the lymphomas seen in this disease are initially more widespread; most common manifestation is painless enlargement of one or more peripheral lymph nodes.
  • Distinct from hodgkin lymphoma both morphologically and biologically, non-hodgkin lymphoma (nhl) is characterized by the absence of reed-sternberg cells, can occur at any age, and usually presents as a localized or generalized lymphadenopathy associated with fever and weight loss. The clinical course varies according to the morphologic type. Nhl is clinically classified as indolent, aggressive, or having a variable clinical course. Nhl can be of b-or t-/nk-cell lineage.
  • Lymphoma is a cancer of a part of the immune system called the lymphatic system. There are many types of lymphoma. One type is called hodgkin disease. The rest are called non-hodgkin lymphoma. Non-hodgkin lymphomas begin when a type of white blood cell, called a t cell or b cell, becomes abnormal. The cell divides again and again, making more and more abnormal cells. These abnormal cells can spread to almost any other part of the body. Most of the time, doctors can’t determine why a person gets non-hodgkin lymphoma. Non-hodgkin lymphoma can cause many symptoms, such as
    • swollen, painless lymph nodes in the neck, armpits or groin
    • unexplained weight loss
    • fever
    • soaking night sweats
    • coughing, trouble breathing or chest pain
    • weakness and tiredness that don’t go away
    • pain, swelling or a feeling of fullness in the abdomen
    your doctor will perform an exam and lab tests to determine if you have lymphoma. nih: national cancer institute
  • Malignant (clonal) proliferation of b- or t- lymphocytes which involves the lymph nodes, bone marrow and/or extranodal sites; general term for various neoplastic diseases of the lymphoid tissue.

Code History

  • 2016 (effective 10/1/2015): New code (first year of non-draft ICD-10-CM)
  • 2017 (effective 10/1/2016): No change
  • 2018 (effective 10/1/2017): No change
  • 2019 (effective 10/1/2018): No change
  • 2020 (effective 10/1/2019): No change
  • 2021 (effective 10/1/2020): No change
  • 2022 (effective 10/1/2021): No change
  • 2023 (effective 10/1/2022): No change
  • 2024 (effective 10/1/2023): No change
  • 2025 (effective 10/1/2024): No change

Code annotations containing back-references to C85.9:

  • Code First: N16

Diagnosis Index entries containing back-references to C85.9:

error: Content is protected !!